The CASCA Study is evaluating an investigational drug called TAK-411 as a potential treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).
Why?
Although there are available CIDP therapies, disease outcomes and response to treatment can be different. There is a need to develop alternative therapies that may lower patient burden.
The CASCA Study researchers are looking to find out if TAK-411’s increased potency compared to other IgG formulations will allow for a smaller dose to be given, which means TAK-411 may have the potential to shorten infusion times and improve the infusion experience. Additionally, TAK-411 may prevent inflammatory processes implicated in CIDP.
WHO?
You may qualify to participate in this study if you are at least 18 years of age and you:
- Have been diagnosed with typical CIDP
- Responded to immunoglobulin G (IgG) treatment in the past
- Are currently receiving immunoglobulin intravenous (IGIV) treatment
You will also need to meet additional criteria, which the study doctor and team will explain.
What will happen?
If you qualify and choose to participate in this study, you will:
- Receive infusions of TAK-411 every 3 weeks for up to 51 weeks if it is noted you are IGIV dependent and respond to the first 2 doses
- · Have frequent visits with the study doctor and team so they can monitor your health closely
- · Receive rescue treatment (IGIV treatment) if your CIDP gets worse at any time during the study
Study infusions and visits may be provided at no cost to you. You may also be reimbursed for pre-approved expenses related to your participation in the study. Please ask your study doctor and team for specific information.
For more information
If you want to learn more about The CASCA Study, you can visit www.theCASCAstudy.com. or scan the code below to view the study video. You can also contact a member of the study team using the information below. They would be glad to talk with you about the study and answer any questions you may have. Thank you for taking time to learn about this CIDP research.
Spotlight
